KADIMASTEM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 494.7 ILa | +1.33% |
|
+7.17% | -16.58% |
| Mar. 28 | Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 28 | IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Companyâs technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.58% | 5.44M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KDST Stock
- News Kadimastem Ltd
- IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company
